{"id":"W4360608257","doi":"10.1200/jco.22.01649","title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":319,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Cohort; Placebo; Hazard ratio; Internal medicine; Prednisone; Oncology; Clinical endpoint; Urology; Progression-free survival; Androgen deprivation therapy; Androgen receptor; Cancer; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008517031,0.0002970743,0.0008600414,0.0003565115,0.0001904494,0.0003822037,0.0003809428,0.0002300099,0.002291009],"category_scores_gemma":[0.0008752279,0.0001087149,0.0005661757,0.0002920152,0.0002970641,0.0002722654,0.0002372108,0.0007641813,0.0003527633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000317533,"about_ca_system_score_gemma":0.0007408243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004056871,"about_ca_topic_score_gemma":0.001711135,"domain_scores_codex":[0.9995016,0.0002277814,0.0000416388,0.00007957662,0.0001068551,0.00004263351],"domain_scores_gemma":[0.9996641,0.00008482734,0.00009209107,0.00002934192,0.00002010363,0.0001094636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2619661,0.006808308,0.009161357,0.003751164,0.001315991,0.0004599422,0.000179457,0.002333643,0.03332445,0.0009140481,0.005098389,0.6746873],"study_design_scores_gemma":[0.302576,0.4805146,0.09952538,0.001289017,0.002439425,0.006402567,0.0002484483,0.004994679,0.01727152,0.004555937,0.08006062,0.0001217497],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9102767,0.07710387,0.0009209982,0.001119286,0.0005152264,0.001127935,0.0007946728,0.0001202144,0.008021052],"genre_scores_gemma":[0.9804991,0.01424679,0.001068042,0.0005680261,0.000292738,0.0005283562,0.0005007889,0.000009759608,0.002286386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002291009,"threshold_uncertainty_score":0.007664144,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2899895319608854,"score_gpt":0.5543641495000348,"score_spread":0.2643746175391494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}